Immunological properties of mononuclear cells from blood stem cell harvests following mobilization with erythropoietin plus G-CSF in cancer patients

被引:7
作者
Joshi, SS
Miller, K
Jackson, JD
Warkentin, P
Kessinger, A
机构
[1] Univ Nebraska, Med Ctr 986395, Dept Cell Biol & Anat, Omaha, NE 68198 USA
[2] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA
[3] Univ Nebraska, Med Ctr, Dept Pediat, Omaha, NE 68198 USA
[4] Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA
关键词
erythropoietin; G-CSF blood stem cells; mobilization; cytotoxic effector cell; functions; phenotypes;
D O I
10.1080/146532400539017
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background Although the recombinant granulocyte colony-stimulating factor (G-CSF) is a good CD34 cell mobilizer; the effects of G-CSF mobilization on the immune effector function of the individual is not always optimal. We studied the functional and phenotypic properties of peripheral blood stem cells (PBSC) collected from 15 cancer patients mobilized with G-CSF plus recombinant erythropoietin (EPO). Methods The patients received EPO (300 U/kg) and (G-CSF 10 mu g/kg) per day as mobilizing cytokines and an autologous graft product was collected with at least daily apheresis procedures until a target number of CD34 cells and mononuclear cells were obtained Mononuclear cells from the first four PBSC collections were tested for their natural killer (NK), activated NK and lymphokine activated killer (LAK) cytotoxicity in vitro against K562 and Raji tumor target cells. Results There was a significant increase in NK, activated NK and LAK cytotoxicity in EPO + G-CSF mobilized cells when compared to mononuclear cells from premobilization blood baseline values Although there was no increase in CD3(+) T cells there was a significant increase in myeloid cells (CD14(+)), B-cells (CD20(+)) and NK cells (CD56(+)) following mobilization. There was no difference in T cell response to the mitogens PHA and Con-A, but there was an increase in B-cell response to PWM following mobilization. Thus, the combination of EPO + G-CSF not only mobilized hematopoietic precursor cells but also increased the number of immune effector cells in the PBSC collections.
引用
收藏
页码:15 / 24
页数:10
相关论文
共 50 条
  • [21] A retrospective study of autologous stem cell mobilization by G-CSF in combination with chemotherapy in patients with multiple myeloma and lymphoma
    Zheng, Gaofeng
    He, Jingsong
    Cai, Zhen
    He, Donghua
    Luo, Yi
    Shi, Jimin
    Wei, Guoqing
    Sun, Jie
    Zheng, Weiyan
    ONCOLOGY LETTERS, 2020, 19 (01) : 1051 - 1059
  • [22] Blood stem cell collections after mobilization with combination chemotherapy containing ifosfamide followed by G-CSF in multiple myeloma
    Straka, C
    Hebart, H
    Adler-Reichel, S
    Werding, N
    Emmerich, B
    Einsele, H
    ONCOLOGY, 2003, 65 : 94 - 98
  • [23] Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers
    Giebel, S.
    Kruzel, T.
    Czerw, T.
    Sadus-Wojciechowska, M.
    Najda, J.
    Chmielowska, E.
    Grosicki, S.
    Jurczyszyn, A.
    Pasiarski, M.
    Nowara, E.
    Glowala-Kosinka, M.
    Chwieduk, A.
    Mitrus, I.
    Smagur, A.
    Holowiecki, J.
    BONE MARROW TRANSPLANTATION, 2013, 48 (07) : 915 - 921
  • [24] Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patients
    K Kolbe
    C Peschel
    B Rupilius
    D Després
    K Burger
    I Sklenar
    L Färber
    C Huber
    HG Derigs
    Bone Marrow Transplantation, 1997, 20 : 1027 - 1032
  • [25] Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patients
    Kolbe, K
    Peschel, C
    Rupilius, B
    Després, D
    Burger, K
    Sklenar, I
    Färber, L
    Huber, C
    Derigs, HG
    BONE MARROW TRANSPLANTATION, 1997, 20 (12) : 1027 - 1032
  • [26] Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers
    S Giebel
    T Kruzel
    T Czerw
    M Sadus-Wojciechowska
    J Najda
    E Chmielowska
    S Grosicki
    A Jurczyszyn
    M Pasiarski
    E Nowara
    M Glowala-Kosinka
    A Chwieduk
    I Mitrus
    A Smagur
    J Holowiecki
    Bone Marrow Transplantation, 2013, 48 : 915 - 921
  • [27] Peripheral Blood Stem Cell Mobilization in Multiple Myeloma Patients Treat in the Novel Therapy-Era With Plerixafor and G-CSF Has Superior Efficacy but Significantly Higher Costs Compared to Mobilization With Low-Dose Cyclophosphamide and G-CSF
    Chaudhary, Lubna
    Awan, Farrukh
    Cumpston, Aaron
    Leadmon, Sonia
    Watkins, Kathy
    Tse, William
    Craig, Michael
    Hamadani, Mehdi
    JOURNAL OF CLINICAL APHERESIS, 2013, 28 (05) : 359 - 367
  • [28] Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients
    S Fruehauf
    G Ehninger
    K Hübel
    J Topaly
    H Goldschmidt
    A D Ho
    S Müller
    M Moos
    K Badel
    G Calandra
    Bone Marrow Transplantation, 2010, 45 : 269 - 275
  • [29] Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients
    Fruehauf, S.
    Ehninger, G.
    Huebel, K.
    Topaly, J.
    Goldschmidt, H.
    Ho, A. D.
    Mueller, S.
    Moos, M.
    Badel, K.
    Calandra, G.
    BONE MARROW TRANSPLANTATION, 2010, 45 (02) : 269 - 275
  • [30] Efficacy and safety of hematopoietic stem cell remobilization with plerixafor plus G-CSF in adult patients with germ cell tumors
    Horwitz, M. E.
    Long, G.
    Holman, P.
    Libby, E.
    Calandra, G. C.
    Schriber, J. R.
    BONE MARROW TRANSPLANTATION, 2012, 47 (10) : 1283 - 1286